Exploration of a Novel Persistent Reversal of Pathological Pain: Mechanisms and Mediators
Abstract
Adenosine 2A receptor agonists when administered intrathecally produces long duration reversal of pain/allodynia in multiple animal models of neuropathic pain. To date we have tested central neuropathy( spinal nerve avulsion), spinal nerve ligation (L5/6 nerve ligation) and a model of sciatic inflammatory neuropathy (SIN). In all of these models the A2AR agonists produces long duration (>4 wk) of pain reversal from a single bolus injection. In addition, we have explored whether the time after injury that the drug is delivered affects the efficacy of the drug. To date, regardless of whether the drug is given in acute neuropathic pain (2 wk) or in well-established neuropathic pain (6 wk after injury), the drug is as effective in both extent of pain reversal and duration. We have begun to explore whether delivery of the drug at the site of injury (perisciatic) is able to reverse the allodynia and the preliminary data looks promising. Lastly, we have begun preliminary studies to identify whether blocking IL-10 at various times after A2AR agonist delivery reverses the efficacy of the drug on pain reversal.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2013
- Accession Number
- ADA582949
Entities
People
- Amanda Ellis
- Linda R. Watkins
- Lisa Loram
Organizations
- University of Colorado Boulder